Roots of the Rescheduling Effort (Image Credits: Unsplash)
Washington – Cannabis companies operating in states where marijuana sales are legal have long navigated a federal roadblock that inflated their taxes and scared off banks. A potential shift in federal policy, accelerated by a December 2025 executive order from President Donald Trump, now promises to ease those pressures.[1][2] The Drug Enforcement Administration could finalize moving marijuana from Schedule I to Schedule III as early as this week, marking the most significant regulatory change since the Controlled Substances Act took effect in 1970.
Roots of the Rescheduling Effort
The process gained momentum in 2023 when the Department of Health and Human Services reviewed marijuana’s status and recommended Schedule III placement, citing accepted medical uses for conditions like chronic pain, nausea, and anorexia.[1] The FDA supported this, backed by data from over 30,000 healthcare practitioners recommending it to more than 6 million patients across 43 jurisdictions. In May 2024, the Justice Department proposed the change, drawing nearly 43,000 public comments.
Trump’s executive order directed the attorney general to expedite the rulemaking under federal law. Despite the push, the DEA has yet to schedule a required administrative hearing, leaving the industry in anticipation amid ongoing delays.[2] This move acknowledges marijuana’s lower abuse potential compared to Schedule I peers like heroin, aligning it instead with substances such as ketamine.
Section 280E: The Tax Burden That Could Vanish
Under current law, Section 280E of the federal tax code bars cannabis businesses from deducting ordinary expenses like rent, salaries, marketing, or utilities because marijuana remains a Schedule I or II substance. This results in effective tax rates often exceeding 70%, far above those for comparable industries.
Reclassification to Schedule III would lift this restriction, allowing full deductions and potentially saving the sector billions. Whitney Economics estimated cannabis operators paid an extra $2.3 billion in federal taxes in 2025 alone due to 280E.[3] Improved cash flow would enable reinvestment in operations, hiring, and debt reduction, addressing chronic issues like slow accounts receivable.
Beau Whitney, chief economist at Whitney Economics, noted that the industry has endured outsized taxation for decades, a policy unchanged despite market evolution.[3] Relief here stands as the most immediate and transformative benefit, potentially stabilizing balance sheets and fueling growth.
Banking Barriers and Investor Appeal
Federal illegality has kept major banks wary, forcing cannabis firms to handle billions in cash or turn to high-interest private lenders. Rescheduling would signal reduced risk, making operators more attractive to traditional finance without fully resolving conflicts.
Stronger financials from tax savings would aid credit assessments, fostering partnerships, though full access likely requires passage of the SAFER Banking Act for safe harbors on deposits and services.[4] Institutional investors, deterred by compliance hurdles, could enter more freely, spurring mergers and acquisitions in a fragmented market.
Ryan Palmquest, senior director of cannabis business at First Citizens Bank, welcomed regulatory clarity, stating it supports clients’ daily operations and sustainable banking ties.[3] Expect heightened scrutiny on anti-money laundering and recordkeeping, but overall, financing costs could drop sharply.
- Current challenges: Cash-heavy operations, limited ACH use (28% of transactions in 2025).
- Post-rescheduling: Projected 42% ACH growth, tech-driven payments, easier onboarding.[4]
Research Momentum and Broader Horizons
Schedule I status has stifled clinical studies, leaving doctors and patients without robust safety and efficacy data. A Schedule III designation would streamline research approvals, accelerating trials on dosing, long-term effects, and therapeutic applications.
This could pave the way for FDA-approved products and insurance coverage, including potential Medicaid pilots. Veterans and seniors, key users for pain management, stand to gain from evidence-based guidance reducing opioid reliance – studies show a 24.8% drop in overdoses in cannabis-friendly states.[3]
Limits and Lingering Hurdles
Reclassification offers no federal legalization, preserving prohibitions on recreational use and interstate sales. State-licensed operators remain federally non-compliant, facing persistent insurance gaps and enforcement risks.
Compliance demands may intensify with stricter testing and labeling, while illicit markets – dominant in places like California – persist due to tax disparities. Stocks of firms like Canopy Growth, Tilray Brands, and Trulieve Cannabis have perked up on rescheduling news, but sustainability hinges on market validation and profitability.[2]
Even as the DEA deliberates, the industry braces for litigation from opponents, underscoring that true transformation demands congressional action.
For cannabis companies, this pivot from pariah to pharmaceutical-like status could mark a turning point, channeling pent-up capital into legitimate expansion. Yet stakeholders from producers to patients await not just the ruling, but its real-world ripple effects in a still-divided regulatory landscape.